GFR | Jotup

CYNTHIA DELGADO AND NEIL POWE NAMED TO TIME100 HEALTH LIST FOR FIGHTING KIDNEY TRANSPLANT BIAS

Retrieved on:

星期四, 五月 2, 2024

The magazine recognized Cynthia Delgado, MD, FASN and Neil Powe, MD, MPH, MBA for their efforts to correct racial bias in the algorithm used to diagnose kidney diseases, an algorithm that often determines access to a kidney transplant.

Key Points:

The magazine recognized Cynthia Delgado, MD, FASN and Neil Powe, MD, MPH, MBA for their efforts to correct racial bias in the algorithm used to diagnose kidney diseases, an algorithm that often determines access to a kidney transplant.
TIME included NKF/ASN Task Force co-chairs in its first-ever list of the 100 most influential people in global health.
Under the updated, race-free algorithm, some Black patients recently received modified times on the wait list for a kidney transplant.
The TIME100 Health List recognizes the world's most influential individuals in health across five categories: Innovators, Titans, Pioneers, Leaders, and Catalysts.

Get Your Study Enrolled - Designing Your Impairment Protocol to Prevent Challenges, Upcoming Webinar Hosted by Xtalks

Retrieved on:

星期一, 四月 22, 2024

MMS, Kidney, University, FASN, Glomerular filtration rate, UNC School of Medicine, Data analysis, MD, GFR, Doctor of Philosophy, Pharmacokinetics, Clinical pharmacology, Project management, Drug development, Associate, Division, Kidney failure, Human body

TORONTO, April 22, 2024 /PRNewswire-PRWeb/ -- As drug development progresses, regulators require clarity on how products are metabolized in the human body, and the risks associated with compounds that may linger in critical organs.

Key Points:

In this free webinar, learn how renal impairment study protocols can be improved to maximize patient enrollment.
Making informed decisions about the design of a study protocol is important, as overly complex protocols can quickly narrow the patient population.
Therefore, making informed decisions about the design of a study protocol is important, as overly complex protocols can quickly narrow the patient population.
Register for this webinar to understand how impairment study protocols can be improved to maximize patient enrollment.

Alport Syndrome Market to Witness Upsurge in Growth at a Massive CAGR of 69% by 2034 | DelveInsight

Retrieved on:

星期三, 四月 17, 2024

LAS VEGAS, April 17, 2024 /PRNewswire/ -- DelveInsight's Alport Syndrome Market Insights report includes a comprehensive understanding of current treatment practices, Alport syndrome emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

Key Points:

Leading Alport syndrome companies such as Eloxx Pharmaceuticals, Chinook Therapeutics (A Novartis company), Bayer, Calliditas Therapeutics, Evotec, and others are developing novel Alport syndrome drugs that can be available in the Alport syndrome market in the coming years.
The disorder manifests in different forms such as autosomal recessive Alport syndrome (ARAS), X-linked Alport syndrome (XLAS), and autosomal dominant Alport syndrome (ADAS).
The X-linked Alport syndrome (XLAS) is the most prevalent subtype of Alport syndrome with around 11K cases in 2023 in the US while autosomal dominant Alport syndrome (ADAS) is the least prevalent subtype of Alport syndrome.
To know more about Alport syndrome treatment guidelines, visit @ Alport Syndrome Management

Alport Syndrome Market to Witness Upsurge in Growth at a Massive CAGR of 69% by 2034 | DelveInsight

Retrieved on:

星期三, 四月 17, 2024

LAS VEGAS, April 17, 2024 /PRNewswire/ -- DelveInsight's Alport Syndrome Market Insights report includes a comprehensive understanding of current treatment practices, Alport syndrome emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

Key Points:

Leading Alport syndrome companies such as Eloxx Pharmaceuticals, Chinook Therapeutics (A Novartis company), Bayer, Calliditas Therapeutics, Evotec, and others are developing novel Alport syndrome drugs that can be available in the Alport syndrome market in the coming years.
The disorder manifests in different forms such as autosomal recessive Alport syndrome (ARAS), X-linked Alport syndrome (XLAS), and autosomal dominant Alport syndrome (ADAS).
The X-linked Alport syndrome (XLAS) is the most prevalent subtype of Alport syndrome with around 11K cases in 2023 in the US while autosomal dominant Alport syndrome (ADAS) is the least prevalent subtype of Alport syndrome.
To know more about Alport syndrome treatment guidelines, visit @ Alport Syndrome Management

Daxor Corporation Acquires Volumex® and Megatope® From Its Existing Supplier Along With Glofil® to Enhance Existing Suite of Diagnostics

Retrieved on:

星期一, 三月 25, 2024

GFR, Commercialization, BVA, Customer experience, Iodine (125I) human albumin, Glomerular filtration rate, Blood volume, Pharmaceutical industry

Oak Ridge, TN, March 25, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today it has entered into a definitive agreement to acquire exclusive and worldwide rights and intellectual property to manufacture from its existing supplier for Volumex and Megatope from privately-held Iso-Tex Diagnostics, Inc. Daxor has also acquired the exclusive rights to Glofil, a drug that measures glomerular filtration rate (GFR), which Iso-Tex has been selling directly to its customer base.

Key Points:

Daxor projects the acquisitions to be cash flow positive and accretive to earnings immediately upon transfer of the manufacturing.
This is due to the embedded revenue streams of the drugs and significantly higher margins that will be achieved with internalized production.
No payments will come due until manufacturing is fully transitioned to Daxor over the next 6-9 months.
The transaction is subject to customary conditions, including receipt of applicable regulatory approvals.

KidneyIntelX™ included in Final KDIGO 2024 Clinical Guideline for Chronic Kidney Disease (CKD)

Retrieved on:

星期四, 三月 14, 2024

Chronic kidney disease, Type 2 diabetes, Disease, CKD, GFR, Risk, Kidney disease, Patient, Evaluation, Doctor of Philosophy, MD, Risk assessment, EGFR, World Kidney Day, Prognosis, FDA, Guideline, Nursing

LONDON and SALT LAKE CITY, March 14, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) (Renalytix) announces that the KidneyIntelX In-Vitro Diagnostic test has been included in the final KDIGO (Kidney Disease Improving Global Outcomes) 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (CKD), published on March 13, 2024.

Key Points:

LONDON and SALT LAKE CITY, March 14, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) (Renalytix) announces that the KidneyIntelX In-Vitro Diagnostic test has been included in the final KDIGO (Kidney Disease Improving Global Outcomes) 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (CKD), published on March 13, 2024.
In the release of the new guideline, timed to coincide with World Kidney Day on March 14, the KDIGO committee highlighted the role of risk prediction in guiding care for patients.
In this context, KidneyIntelX is recommended for use as an externally validated tool for predicting disease progression in people with CKD stages G1-G3.
In the KDIGO announcement of the publication of the 2024 CKD guideline, Adeera Levin MD, one of the Guideline Committee Co-Chairs said, “Recent advancements in GFR evaluation, risk prediction, and the arrival of novel treatments are poised to enhance CKD prognosis and management.

Greenfire Resources Ltd. (TSX: GFR) Opens the Market

Retrieved on:

星期四, 三月 21, 2024

GFR, Multimedia, TSX, Steam, Drainage, Toronto Stock Exchange

TORONTO, March 21, 2024 /PRNewswire/ - Robert Logan, President and Chief Executive Officer, Greenfire Resources Ltd. (NYSE: GFR) (TSX: GFR) ("Greenfire" or the "Company"), and his team joined Robert Peterman, Chief Commercial Officer, Toronto Stock Exchange (TSX), to open the market and celebrate the Company's listing on TSX.

Key Points:

TORONTO, March 21, 2024 /PRNewswire/ - Robert Logan, President and Chief Executive Officer, Greenfire Resources Ltd. (NYSE: GFR) (TSX: GFR) ("Greenfire" or the "Company"), and his team joined Robert Peterman, Chief Commercial Officer, Toronto Stock Exchange (TSX), to open the market and celebrate the Company's listing on TSX.
Greenfire is an intermediate, lower-cost and growth-oriented oil sands producer focused on the sustainable development of its concentrated Tier-1 assets in Western Canada using steam assisted gravity drainage.
Greenfire operates two facilities with major infrastructure in place that produced approximately 20,800 bbls/d net to the Company in December 2023.
View original content to download multimedia: https://www.prnewswire.com/news-releases/greenfire-resources-ltd-tsx-gfr...

CalciMedica Presents Data from Preclinical Studies of Auxora in Acute Kidney Injury at the 29th International AKI & CRRT Conference

Retrieved on:

星期三, 三月 13, 2024

LA JOLLA, Calif., March 13, 2024 /PRNewswire/ -- CalciMedica Inc. (CalciMedica or the Company) (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic diseases, last evening presented data from preclinical studies of Auxora™ in acute kidney injury (AKI) at the 29th International Acute Kidney Injury and Continuous Renal Replacement Therapy Conference (AKI & CRRT) in San Diego, CA. David Basile, Ph.D., Professor of Anatomy, Cell Biology and Physiology at Indiana University, gave an oral and poster presentation entitled "The Store-Operated Calcium Channel Inhibitor Auxora Improves Renal Function Following Ischemia-Induced Acute Kidney Injury in Rats."

Key Points:

In rats with kidney injury akin to Stage 3 AKI, the rats treated with placebo died while those on Auxora survived and showed modest recovery of GFR.
We are excited as these studies support clinical observations of Auxora that suggest the drug may be beneficial for AKI patients."
The data presented at AKI & CRRT was from a series of studies referred to as Study 1 and Study 2.
These results indicate that Auxora has the ability to hasten the recovery of kidney function and improve survival in rat models of AKI.

CalciMedica Announces FDA Clearance of IND Application for Phase 2 Trial of Auxora™ for the Treatment of Severe Acute Kidney Injury

Retrieved on:

星期二, 二月 13, 2024

LA JOLLA, Calif., Feb. 13, 2024 /PRNewswire/ -- CalciMedica, Inc. (CalciMedica or the Company) (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic diseases, today announced the clearance of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) for the Company's lead product candidate, Auxora™, a potent and selective small molecule inhibitor of Orai1-containing CRAC channels, to be evaluated in a Phase 2 trial in acute kidney injury (AKI) with associated acute hypoxemic respiratory failure (AHRF). CalciMedica expects to initiate the trial, named KOURAGE, in the first half of 2024 and data expected in 2025.

Key Points:

CalciMedica expects to initiate the trial, named KOURAGE, in the first half of 2024 and data expected in 2025.
"Through KOURAGE, we aim to determine how Auxora can benefit patients with severe AKI and potentially reduce the high mortality rate associated with this disease."
AKI is classified as stages 1, 2 and 3 depending on the degree of kidney injury.
A single dose of Auxora after IRI increased GFR by 61% and decreased mononuclear (inflammatory) cell infiltration by 30%.

NANO Nuclear Energy Chief Executive Officer to Present Before New Hampshire Commission Investigating the Implementation of Next Generation Nuclear Reactor Technology in the State

Retrieved on:

星期一, 十月 16, 2023

Partnership, ZEUS, Wind, Consumer protection, MSR, Safety, ODIN, Carbon, NANO, State, New Hampshire House of Representatives, Hampshire, Generation, Nuclear energy, GFR, New Hampshire State House, Research, Uranium mining, Renewable energy

New York, N.Y., Oct. 16, 2023 (GLOBE NEWSWIRE) -- NANO Nuclear Energy Inc. (“NANO Nuclear”), an emerging microreactor and advanced nuclear technology company led by a world-class nuclear engineering team developing proprietary, portable and carbon free energy solutions, is pleased to announce that Chief Executive Officer James Walker will provide counsel and testimony on November 6th, 2023 alongside fellow experts in the field for New Hampshire’s Commission To Investigate The Implementation Of Next Generation Nuclear Reactor Technology on the state-wide implementation of new-generation technologies, including “Generation IV” reactors.

Key Points:

“New Hampshire has a plethora of experience with nuclear energy, but I would like to thank NANO Nuclear and Mr. Walker for contributing to our inquiry into advanced nuclear technologies, including Generation IV reactors and microreactors,” said Rep. Keith Ammon, New Hampshire State Representative and Chair, Nuclear Technology Study Commission.
Established under HB543, a bill sponsored by New Hampshire State Representatives including Rep. Keith Ammon (R-New Boston), the commission is tasked with assessing developments in nuclear energy technology, notably Generation IV reactors.
“At the start of this year, we were encouraged by the Federal government's commitment to advancing the domestic nuclear energy sector,” said James Walker, Chief Executive Officer of NANO Nuclear Energy.
“It is time to move past the stigmas of the past when it comes to nuclear energy, and I applaud New Hampshire for taking a proactive stance in investigating our novel nuclear technologies.”